Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China. CA Cancer J Clin. 2016;66(2):115–32 (Epub 2016/01/26).

Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479–85 (Epub 2000/06/07).

Gettinger S, Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med. 2011;32(4):839–51 (Epub 2011/11/08).

Wu J, Peng W, Qin R, Zhou H. Crataegus pinnatifida: chemical constituents, pharmacology, and potential applications. Molecules. 2014;19(2):1685–712 (Epub 2014/02/04).

Lee CY, Chien YS, Chiu TH, Huang WW, Lu CC, Chiang JH, et al. Apoptosis triggered by vitexin in U937 human leukemia cells via a mitochondrial signaling pathway. Oncol Rep. 2012;28(5):1883–8 (Epub 2012/09/04).

He JD, Wang Z, Li SP, Xu YJ, Yu Y, Ding YJ, et al. Vitexin suppresses autophagy to induce apoptosis in hepatocellular carcinoma via activation of the JNK signaling pathway. Oncotarget. 2016;7(51):84520–32 (Epub 2016/09/03).

Zhang G, Li D, Chen H, Zhang J, Jin X. Vitexin induces G2/Mphase arrest and apoptosis via Akt/mTOR signaling pathway in human glioblastoma cells. Mol Med Rep. 2018;17(3):4599–604 (Epub 2018/01/13).

Racher AJ, Looby D, Griffiths JB. Use of lactate dehydrogenase release to assess changes in culture viability. Cytotechnology. 1990;3(3):301–7 (Epub 1990/05/01).

Cossarizza A, Salvioli S. Flow cytometric analysis of mitochondrial membrane potential using JC-1. Current protocols in cytometry. 2001;Chapter 9: Unit 9 14. (Epub 2008/09/05).

Sun Z, Wang Z, Liu X, Wang D. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anticancer Drugs. 2015;26(1):1–14 (Epub 2014/10/12).

Eaton KD, Martins RG. Maintenance chemotherapy in non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):815–21 (Epub 2010/08/04).

An F, Wang S, Tian Q, Zhu D. Effects of orientin and vitexin from Trollius chinensis on the growth and apoptosis of esophageal cancer EC-109 cells. Oncol Lett. 2015;10(4):2627–33 (Epub 2015/12/02).

Portugal J, Bataller M, Mansilla S. Cell death pathways in response to antitumor therapy. Tumori. 2009;95(4):409–21 (Epub 2009/10/28).

Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59 (Epub 2007/12/22).

Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305(5684):626–9 (Epub 2004/08/03).

Pal I, Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin. 2012;33(12):1441–58 (Epub 2012/09/18).

Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010;7(4):209–19 (Epub 2010/03/18).

Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012;7(8):1315–26 (Epub 2012/06/01).